Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US-10028983-B2 · Jul 24, 2018 · US
Lactobacillus having various functions, and use thereof
US11202811B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11202811-B2 |
| Application number | US-201615759915-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 7, 2016 |
| Priority date | Sep 15, 2015 |
| Publication date | Dec 21, 2021 |
| Grant date | Dec 21, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activities such as antioxidant activity, β-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity or tight junction protein expression-inducing activity. Accordingly, a certain Lactobacillus sp. strain, certain Bifidobacterium sp. strain or mixture thereof according to the present invention may be used as a functional food or medicinal material useful for the prevention, alleviation or treatment of intestinal damage, liver injury, allergic disease, inflammatory disease, or obesity.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating one or more diseases selected from a group consisting of intestinal damage, liver injury, allergic disease and inflammatory disease, comprising administering a composition comprising Lactobacillus plantarum LC27 (accession number: KCCM 11801P), a culture thereof, a lysate thereof or an extract thereof to a subject, wherein the intestinal damage is intestinal permeability syndrome; the liver injury is selected from a group consisting of hepatitis, fatty liver and liver cirrhosis; the allergic disease is selected from a group consisting of atopic dermatitis, asthma, pharyngitis and chronic dermatitis and wherein the inflammatory disease is selected from a group consisting of gastritis, gastric ulcer, colitis and arthritis; and wherein the Lactobacillus plantarum LC27 has antioxidant activity, beta-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity and tight junction protein expression-inducing activity. 2. The method according to claim 1 , wherein the Lactobacillus plantarum LC27 comprises a 16S rDNA nucleotide sequence of SEQ ID NO: 5. 3. The method according to claim 1 , wherein the composition further comprises one or more lactic acid bacteria selected from a group consisting of Lactobacillus brevis CH23 (accession number: KCCM 11762P), Bifidobacterium longum CH57 (accession number: KCCM 11764P), Lactobacillus plantarum LC5 (accession number: KCCM 11800P) and Bifidobacterium longum LC67 (accession number: KCCM 11802P). 4. The method according to claim 1 , wherein the composition further comprises Bifidobacterium longum LC67 (accession number: KCCM 11802P), a culture thereof, a lysate thereof or an extract thereof.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
- A61K35/747Primary
Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title
- A61K35/745Primary
Bifidobacteria · CPC title
- C12N1/20Primary
Bacteria; Culture media therefor · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11202811B2 cover?
- The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activi…
- Who is the assignee on this patent?
- Univ Industry Cooperation Group Kyung Hee Univ, Navipharm Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K35/747. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).